Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge

CNBC Published Updated Stocks
Sign in to save

Affected assets and topics

REVENUE

Expected market reaction

Bullish Confidence 60% How confidence is read Horizon: Short term Impact: Low

Evidence trail

Evidence
Source CNBC
Claim Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge
AI inference Bullish · 60%
Generated 2026-08-05 10:57

AI provenance

Analysed by Rule-Based Analysis not AI Methodology v1.0 Generated
Technical identifiers
Provider tag
free-analysis-rule-based-analysis
Analysis version
free-analysis-rule-based-analysis
Article id
115000

Original source

Eli Lilly now expects 2026 revenue to come in between $85 billion and $87 billion, up from a previous guidance of $82 billion and $85 billion.

Read the full article on CNBC

Original article published by CNBC on August 5, 2026. Analysis and insights provided by AnalystMarkets AI.

Related coverage

This model on similar stories

Rule-Based Analysis · 34.2% correct across 732 scored calls on equities See the full record